Two-year results of the ATTRACT trial show that pharmacomechanical catheter-directed thrombolysis (PCDT) to treat deep-vein thrombosis does not reduce the patients’ chances of developing post-thrombotic syndrome, but does increase their risk of major bleeding compared anticoagulation drug therapy alone.
“[ATTRACT] provides the first high quality data on PCDT and will enable doctors to target its use to patients who may benefit, prevent costly and unnecessary procedures in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?